Dr. Marwan Fakih (IMAGE)
Caption
“This is the first Phase 3 clinical trial to show a benefit over standard of care in patients with the KRAS G12C mutation whose cancer progressed after receiving standard chemotherapy. The efficacy results from our study are promising in this population with unmet needs and should set a new standard of care for metastatic colorectal cancer patients with KRAS G12C mutation who progressed following prior standard treatments,” said Marwan Fakih, M.D., professor in the Department of Medical Oncology & Therapeutics Research and the Judy & Bernard Briskin Distinguished Director of Clinical Research at City of Hope. Fakih is lead author of the New England Journal of Medicine study and principal investigator of the clinical trial at City of Hope.
Credit
City of Hope
Usage Restrictions
Please use photo credit
License
Original content